Thomas Baumert

Thomas Baumert (born May 20, 1965) is a German-French physician-scientist and entrepreneur. He is a Professor of Medicine at the University of Strasbourg and the Chief of the Gastroenterology-Hepatology Service at the . He is the founder of Alentis Therapeutics, a clinical-stage biotech company in Basel. He works on the basic, translational, and clinical investigation of liver disease and cancer.

Baumert and his teams have discovered and developed novel strategies to treat fibrosis and cancer. He has published more than 400 scientific articles including in ''The New England Journal of Medicine'', ''Cell'', ''Nature'', and ''Science Translational Medicine''. His work has been recognized by several awards and honors, including the Galien Prize and the Inserm Research Award. Provided by Wikipedia
Showing 1 - 20 results of 50 for search 'Thomas F. Baumert', query time: 0.06s Refine Results
  1. 1
    Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine

    Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine by Steven K. H. Foung, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert

    Published 2018-11-01
    Get full text
    Article
  2. 2
    Inflammation-related prognostic markers in resected hepatocellular carcinoma

    Inflammation-related prognostic markers in resected hepatocellular carcinoma by Fabio Giannone, Fabio Giannone, Fabio Giannone, Nevena Slovic, Patrick Pessaux, Patrick Pessaux, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert, Joachim Lupberger

    Published 2023-12-01
    Get full text
    Article
  3. 3
    Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma

    Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma by Thomas F. Baumert, Yujin Hoshida

    Published 2019-05-01
    Get full text
    Article
  4. 4
    Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges

    Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges by Joachim Lupberger, Thomas F. Baumert

    Published 2021-12-01
    Get full text
    Article
  5. 5
    Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease

    Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease by Armando Andres Roca Suarez, Armando Andres Roca Suarez, Armando Andres Roca Suarez, Armando Andres Roca Suarez, Barbara Testoni, Barbara Testoni, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert, Joachim Lupberger, Joachim Lupberger

    Published 2021-02-01
    Get full text
    Article
  6. 6
    Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

    Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives by Natascha Roehlen, Emilie Crouchet, Thomas F. Baumert

    Published 2020-04-01
    Get full text
    Article
  7. 7
    Hepatitis C virus infection and related liver disease: the quest for the best animal model

    Hepatitis C virus infection and related liver disease: the quest for the best animal model by Laurent eMailly, Laurent eMailly, Eric eRobinet, Eric eRobinet, Eric eRobinet, Philip eMeuleman, Thomas F. Baumert, Thomas F. Baumert, Thomas F. Baumert, Mirjam B. Zeisel, Mirjam B. Zeisel

    Published 2013-07-01
    Get full text
    Article
  8. 8
    Tight Junction Protein Signaling and Cancer Biology

    Tight Junction Protein Signaling and Cancer Biology by Zeina Nehme, Natascha Roehlen, Punita Dhawan, Thomas F. Baumert

    Published 2023-01-01
    Get full text
    Article
  9. 9
    Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection

    Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection by Margaux J. Heuschkel, Thomas F. Baumert, Eloi R. Verrier

    Published 2021-08-01
    Get full text
    Article
  10. 10
    Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure

    Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure by Stephen J. Polyak, I. Nicholas Crispe, Thomas F. Baumert

    Published 2021-01-01
    Get full text
    Article
  11. 11
    Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection

    Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection by Mirjam B. Zeisel, Emilie Crouchet, Thomas F. Baumert, Catherine Schuster

    Published 2015-11-01
    Get full text
    Article
  12. 12
    Oncogenic Signaling Induced by HCV Infection

    Oncogenic Signaling Induced by HCV Infection by Alessia Virzì, Armando Andres Roca Suarez, Thomas F. Baumert, Joachim Lupberger

    Published 2018-10-01
    Get full text
    Article
  13. 13
    Polymorphisms within DIO2 and GADD45A genes increase the risk of liver disease progression in chronic hepatitis b carriers

    Polymorphisms within DIO2 and GADD45A genes increase the risk of liver disease progression in chronic hepatitis b carriers by Magda Rybicka, Eloi R. Verrier, Thomas F. Baumert, Krzysztof Piotr Bielawski

    Published 2023-04-01
    Get full text
    Article
  14. 14
    Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses

    Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses by Clotilde Muller, Sophie Alain, Thomas F. Baumert, Gaëtan Ligat, Sébastien Hantz

    Published 2021-02-01
    Get full text
    Article
  15. 15
    Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development

    Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development by Alessia Virzì, Victor Gonzalez-Motos, Simona Tripon, Thomas F. Baumert, Joachim Lupberger

    Published 2021-03-01
    Get full text
    Article
  16. 16
    Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences

    Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences by Zakaria Boulahtouf, Alessia Virzì, Thomas F. Baumert, Eloi R. Verrier, Joachim Lupberger

    Published 2022-03-01
    Get full text
    Article
  17. 17
    Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E.

    Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. by Mathieu Lefèvre, Daniel J Felmlee, Marie Parnot, Thomas F Baumert, Catherine Schuster

    Published 2014-01-01
    Get full text
    Article
  18. 18
    Viral manipulation of STAT3: Evade, exploit, and injure.

    Viral manipulation of STAT3: Evade, exploit, and injure. by Armando Andres Roca Suarez, Nicolaas Van Renne, Thomas F Baumert, Joachim Lupberger

    Published 2018-03-01
    Get full text
    Article
  19. 19
    Host-targeting therapies for hepatitis C virus infection: current developments and future applications

    Host-targeting therapies for hepatitis C virus infection: current developments and future applications by Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert

    Published 2018-03-01
    Get full text
    Article
  20. 20
    Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease

    Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease by Thomas F. Baumert, Catherine Schuster, Mathieu Lefevre, Mohamed Lamine Hafirassou, Daniel J. Felmlee

    Published 2013-05-01
    Get full text
    Article

Search Tools: